Benutzer: Gast  Login
Titel:

CMV seropositivity is a potential novel risk factor for severe COVID-19 in non-geriatric patients.

Dokumenttyp:
Journal Article; Research Support, Non-U.S. Gov't
Autor(en):
Weber, Simone; Kehl, Victoria; Erber, Johanna; Wagner, Karolin I; Jetzlsperger, Ana-Marija; Burrell, Teresa; Schober, Kilian; Schommers, Philipp; Augustin, Max; Crowell, Claudia S; Gerhard, Markus; Winter, Christof; Moosmann, Andreas; Spinner, Christoph D; Protzer, Ulrike; Hoffmann, Dieter; D'Ippolito, Elvira; Busch, Dirk H
Abstract:
BACKGROUND: COVID-19 has so far affected more than 250 million individuals worldwide, causing more than 5 million deaths. Several risk factors for severe disease have been identified, most of which coincide with advanced age. In younger individuals, severe COVID-19 often occurs in the absence of obvious comorbidities. Guided by the finding of cytomegalovirus (CMV)-specific T cells with some cross-reactivity to SARS-CoV-2 in a COVID-19 intensive care unit (ICU) patient, we decided to investigate whether CMV seropositivity is associated with severe or critical COVID-19. Herpes simplex virus (HSV) serostatus was investigated as control. METHODS: National German COVID-19 bio-sample and data banks were used to retrospectively analyze the CMV and HSV serostatus of patients who experienced mild (n = 101), moderate (n = 130) or severe to critical (n = 80) disease by IgG serology. We then investigated the relationship between disease severity and herpesvirus serostatus via statistical models. RESULTS: Non-geriatric patients (< 60 years) with severe COVID-19 were found to have a very high prevalence of CMV-seropositivity, while CMV status distribution in individuals with mild disease was similar to the prevalence in the German population; interestingly, this was not detectable in older patients. Prediction models support the hypothesis that the CMV serostatus, unlike HSV, might be a strong biomarker in identifying younger individuals with a higher risk of developing severe COVID-19, in particular in absence of other co-morbidities. CONCLUSIONS: We identified 'CMV-seropositivity' as a potential novel risk factor for severe COVID-19 in non-geriatric individuals in the studied cohorts. More mechanistic analyses as well as confirmation of similar findings in cohorts representing the currently most relevant SARS-CoV-2 variants should be performed shortly.
Zeitschriftentitel:
PLoS ONE
Jahr:
2022
Band / Volume:
17
Heft / Issue:
5
Volltext / DOI:
doi:10.1371/journal.pone.0268530
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/35613127
Print-ISSN:
1932-6203
TUM Einrichtung:
608; Institut für Klinische Chemie und Pathobiochemie (Prof. Ruland); Institut für Medizinische Mikrobiologie, Immunologie und Hygiene (Prof. Busch); Institut für Virologie (Prof. Protzer); Klinik und Poliklinik für Innere Medizin II, Gastroenterologie (Prof. Schmid); Lehrstuhl für Medizinische Informatik (Prof. Boeker)
 BibTeX
Vorkommen: